Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Sign Up
PubMed This is a summary of 25 peer-reviewed journal articles Updated
Medical Genetics

Subtypes and Risks: Your Genetic Roadmap

At a Glance

Hermansky-Pudlak syndrome has 11 genetic subtypes grouped into four protein complexes. The subtype can guide monitoring for lung scarring, bowel inflammation, low white blood cell counts, or neurologic problems, but it cannot predict one person’s exact future.

While all types of Hermansky-Pudlak Syndrome (HPS) share the core features of albinism and bleeding risks, your specific genetic subtype acts as a roadmap for your future health care [1][2]. Scientists have identified 11 different subtypes, each caused by a mutation in a different gene. These genes are grouped into four “protein complexes”—the cellular machinery responsible for moving vital materials within your cells [3][4].

It is important to remember that these subtype trends guide your doctor’s surveillance plan; they do not predict an individual patient’s exact outcome.

The BLOC-3 Group: HPS-1 and HPS-4

Subtypes HPS-1 and HPS-4 are grouped under the BLOC-3 complex [4]. These subtypes require the most vigilant monitoring because they carry a strong association with two specific systemic complications:

  • Pulmonary Fibrosis: This is a progressive scarring of the lungs that typically becomes evident in middle adulthood (often between ages 30 and 50) [5][6]. For those with HPS-1 or HPS-4, monitoring lung health is a lifelong priority, as this scarring can eventually lead to respiratory failure [7][8].
  • Inflammatory Bowel Disease (IBD): A subset of patients (estimated at around 14% in some research cohorts) develop a condition that looks very similar to Crohn’s disease [9]. It can cause severe abdominal pain, diarrhea, and weight loss, and can sometimes appear as early as infancy [10][11].

The AP-3 Group: HPS-2 and HPS-10

Subtypes HPS-2 and HPS-10 affect the AP-3 complex, which is involved in both pigment and immune system function [12][13].

  • HPS-2: This subtype is unique because it often causes neutropenia—a low level of white blood cells—which leads to frequent infections [14]. Unlike HPS-1, interstitial lung disease in HPS-2 can begin much earlier, sometimes appearing in early childhood [14][15].
  • HPS-10: This is a very rare subtype. Small case series have reported severe neurologic symptoms in some individuals, including seizures, developmental delays, and hearing impairment, alongside the typical HPS features [13][16].

The BLOC-2 and BLOC-1 Groups

Some subtypes are generally associated with less severe systemic risks, though bleeding risk is present across all forms of HPS.

  • BLOC-2 (HPS-3, HPS-5, HPS-6): People with these subtypes often have more pigment (darker hair or skin) than those with HPS-1 [1][17]. While they are less associated with progressive lung scarring, HPS-6 has been linked to bowel disease in a few reports, and all three carry the standard HPS bleeding risk [18][10].
  • BLOC-1 (HPS-7, HPS-8, HPS-9, HPS-11): These are exceptionally rare subtypes. While limited reports suggest they may follow a milder clinical course in many respects, severe very-early-onset IBD has been reported in HPS-7 [19]. Doctors monitor these patients closely for any emerging symptoms [20].

The Role of Heritage and “Founder Effects”

In certain communities, specific HPS genetic variants are much more common due to a founder effect—where a small group of ancestors passed down a specific genetic mutation [21].

  • Puerto Rican Heritage: A specific mutation in HPS-1 and another in HPS-3 are highly prevalent. In one study of Puerto Rican patients, roughly 73% had HPS-1 and 26% had HPS-3 [22].
  • Ashkenazi Jewish Heritage: A specific mutation in the HPS-3 gene is found as a “carrier” frequency in approximately 1 in every 200 people of Ashkenazi descent [23] (meaning they carry one copy; two copies are needed for the disease).

Knowing your heritage can help your doctors know which genes to test first, but a full genetic panel is always recommended to ensure nothing is missed [24][25]. Understanding your subtype is the first step in creating a personalized plan to protect your health [1].

Common questions in this guide

How many Hermansky-Pudlak syndrome subtypes are there?
Researchers have identified 11 HPS subtypes, each linked to changes in a different gene. The subtypes are grouped into four cellular protein complexes—BLOC-1, BLOC-2, BLOC-3, and AP-3—which help clinicians anticipate possible health risks but cannot predict an individual’s exact outcome.
Which HPS subtypes have the highest risk of lung scarring?
HPS-1 and HPS-4 have the strongest association with progressive pulmonary fibrosis, a type of lung scarring that often becomes evident in middle adulthood. HPS-2 can also cause interstitial lung disease, but it may begin in early childhood.
Which HPS subtypes are linked to bowel disease?
HPS-1 and HPS-4 can be associated with inflammatory bowel disease that resembles Crohn’s disease. Bowel disease has also been reported in HPS-6, and severe very-early-onset inflammatory bowel disease has been reported in HPS-7, although not everyone with these subtypes develops it.
What does HPS-2 mean for infection risk?
HPS-2 often causes neutropenia, which means having too few neutrophils, a type of white blood cell that helps fight infection. This can lead to frequent infections and is one reason doctors may monitor absolute neutrophil counts.
Can ancestry affect which HPS mutation is found?
Yes. Founder variants are more common in some communities, including specific HPS-1 and HPS-3 variants among people with Puerto Rican heritage and an HPS-3 carrier variant among people of Ashkenazi Jewish descent. Heritage can guide which genes are tested first, but a full genetic panel is recommended to avoid missing another subtype.
How does knowing my HPS subtype change monitoring?
Your subtype can help your care team decide when to assess lung function and imaging, watch for bowel symptoms, check white blood cell counts, or track neurologic and developmental concerns. These patterns guide surveillance but do not determine exactly what will happen to you or your child.

Questions For You

Answer a question to get research tailored to you. Your answers are private.

Get notified when new evidence is published on Hermansky-Pudlak syndrome.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Which specific protein complex—BLOC-1, 2, 3, or AP-3—is affected by my (or my child's) genetic subtype?
  2. 2.Based on this subtype, what is the specific risk for developing pulmonary fibrosis or inflammatory bowel disease?
  3. 3.Should we be monitoring absolute neutrophil counts (ANCs) to check for immune system risks associated with subtypes like HPS-2?
  4. 4.At what age do you recommend starting baseline lung function tests and imaging for this specific subtype?
  5. 5.If we have Puerto Rican or Ashkenazi Jewish heritage, did the genetic test look for the specific 'founder' mutations common in those populations?

References

References (25)
  1. 1

    Hermansky-Pudlak syndrome: Mutation update.

    Huizing M, Malicdan MCV, Wang JA, et al.

    Human mutation 2020; (41(3)):543-580 doi:10.1002/humu.23968.

    PMID: 31898847
  2. 2

    Impairment of Renal Function in Hermansky-Pudlak Syndrome.

    Yokoyama T, O'Brien KJ, Franklin TM, et al.

    American journal of nephrology 2025; (56(1)):25-34 doi:10.1159/000541835.

    PMID: 39383848
  3. 3

    A Novel Likely Pathogenic Variant in the BLOC1S5 Gene Associated with Hermansky-Pudlak Syndrome Type 11 and an Overview of Human BLOC-1 Deficiencies.

    Boeckelmann D, Wolter M, Käsmann-Kellner B, et al.

    Cells 2021; (10(10)) doi:10.3390/cells10102630.

    PMID: 34685610
  4. 4

    Cryo-EM structure of the BLOC-3 complex provides insights into the pathogenesis of Hermansky-Pudlak syndrome.

    Yong X, Jia G, Yang Q, et al.

    Nature communications 2025; (16(1)):2967 doi:10.1038/s41467-025-58235-1.

    PMID: 40140412
  5. 5

    Hermansky-Pudlak syndrome pulmonary fibrosis: a rare inherited interstitial lung disease.

    Yokoyama T, Gochuico BR

    European respiratory review : an official journal of the European Respiratory Society 2021; (30(159)) doi:10.1183/16000617.0193-2020.

    PMID: 33536261
  6. 6

    Hermansky-Pudlak Syndrome and Lung Disease: Pathogenesis and Therapeutics.

    Velázquez-Díaz P, Nakajima E, Sorkhdini P, et al.

    Frontiers in pharmacology 2021; (12()):644671 doi:10.3389/fphar.2021.644671.

    PMID: 33841163
  7. 7

    Hermansky-Pudlak Syndrome.

    Wang JY, Young LR

    Clinics in chest medicine 2025; (46(4)):701-710 doi:10.1016/j.ccm.2025.07.009.

    PMID: 41110930
  8. 8

    A novel mutation causes Hermansky-Pudlak syndrome type 4 with pulmonary fibrosis in 2 siblings from China.

    Wu W, Lin K, Yang Y, et al.

    Medicine 2019; (98(33)):e16899 doi:10.1097/MD.0000000000016899.

    PMID: 31415434
  9. 9

    Inflammatory bowel disease in Hermansky-Pudlak syndrome: a retrospective single-centre cohort study.

    O'Brien KJ, Parisi X, Shelman NR, et al.

    Journal of internal medicine 2021; (290(1)):129-140 doi:10.1111/joim.13224.

    PMID: 33423334
  10. 10

    Infantile-onset inflammatory bowel disease in a patient with Hermansky-Pudlak syndrome: a case report.

    Ishihara J, Mizuochi T, Uchida T, et al.

    BMC gastroenterology 2019; (19(1)):9 doi:10.1186/s12876-019-0929-9.

    PMID: 30634918
  11. 11

    Two Complex Cases of Hermansky-Pudlak Syndrome Highlight a Potential Biologic Explanation for an Associated Crohn's Disease Phenotype.

    Sofia MA, Sakuraba A, Rubin DT

    ACG case reports journal 2017; (4()):e14 doi:10.14309/crj.2017.14.

    PMID: 28144619
  12. 12

    Hermansky-Pudlak Syndrome: Spectrum in Oman.

    Nazir HF, Al Sukaiti N, Khater D, et al.

    Journal of pediatric hematology/oncology 2023; (45(3)):e389-e394 doi:10.1097/MPH.0000000000002552.

    PMID: 36162005
  13. 13

    Biallelic mutations in AP3D1 cause Hermansky-Pudlak syndrome type 10 associated with immunodeficiency and seizure disorder.

    Mohammed M, Al-Hashmi N, Al-Rashdi S, et al.

    European journal of medical genetics 2019; (62(11)):103583 doi:10.1016/j.ejmg.2018.11.017.

    PMID: 30472485
  14. 14

    Hermansky-Pudlak syndrome type 2 manifests with fibrosing lung disease early in childhood.

    Hengst M, Naehrlich L, Mahavadi P, et al.

    Orphanet journal of rare diseases 2018; (13(1)):42 doi:10.1186/s13023-018-0780-z.

    PMID: 29580292
  15. 15

    Hermansky-Pudlak syndrome with interstitial lung disease: A holistically worked up couplet.

    Gupta A, Utpat K, Desai U, Joshi JM

    Lung India : official organ of Indian Chest Society 2019; (36(4)):345-348 doi:10.4103/lungindia.lungindia_258_18.

    PMID: 31290422
  16. 16

    Hermansky-Pudlak syndrome-rare type 10 with AP3D1 mutation.

    Balaraddi V, Nawlakhe K, K S, Bandiya P

    Oxford medical case reports 2025; (2025(9)):omaf184 doi:10.1093/omcr/omaf184.

    PMID: 41025021
  17. 17

    Genetic variants and mutational spectrum of Chinese Hermansky-Pudlak syndrome patients.

    Liu T, Yuan Y, Bai D, et al.

    Pigment cell & melanoma research 2021; (34(1)):111-121 doi:10.1111/pcmr.12916.

    PMID: 32725903
  18. 18

    Clinico-molecular analysis of eleven patients with Hermansky-Pudlak type 5 syndrome, a mild form of HPS.

    Michaud V, Lasseaux E, Plaisant C, et al.

    Pigment cell & melanoma research 2017; (30(6)):563-570 doi:10.1111/pcmr.12608.

    PMID: 28640947
  19. 19

    Novel variants in the BLOC1S3 gene in patients presenting a mild form of Hermansky-Pudlak syndrome.

    Pennamen P, Tingaud-Sequeira A, Michaud V, et al.

    Pigment cell & melanoma research 2021; (34(1)):132-135 doi:10.1111/pcmr.12915.

    PMID: 32687635
  20. 20

    A novel BLOC1S5-related HPS-11 patient and zebrafish with bloc1s5 disruption.

    Zhong Z, Wu Z, Zhang J, Chen J

    Pigment cell & melanoma research 2021; (34(6)):1112-1119 doi:10.1111/pcmr.12995.

    PMID: 34058075
  21. 21

    Hermansky-Pudlak Syndrome.

    De Jesus Rojas W, Young LR

    Seminars in respiratory and critical care medicine 2020; (41(2)):238-246 doi:10.1055/s-0040-1708088.

    PMID: 32279294
  22. 22

    Differences in Visual Acuity Among Hermansky-Pudlak Syndrome Subtypes.

    Jiménez-Berríos GA, Vázquez-Folch SJ, Izquierdo N

    Cureus 2025; (17(5)):e83729 doi:10.7759/cureus.83729.

    PMID: 40486412
  23. 23

    Oculocutaneous albinism and bleeding diathesis due to a novel deletion in the HPS3 gene.

    Marek-Yagel D, Abudi-Sinreich S, Macarov M, et al.

    Frontiers in genetics 2022; (13()):936064 doi:10.3389/fgene.2022.936064.

    PMID: 36046236
  24. 24

    After an initial Hermansky-Pudlak syndrome clinical diagnosis, molecular testing reveals variants for oculocutaneous albinism type 1B: A case report.

    Serrano-González J, Montes-Rodríguez I, Renta JY, et al.

    Molecular genetics & genomic medicine 2024; (12(7)):e2493 doi:10.1002/mgg3.2493.

    PMID: 38994739
  25. 25

    Instability of BLOC-2 and BLOC-3 in Chinese patients with Hermansky-Pudlak syndrome.

    Wei A, Yuan Y, Qi Z, et al.

    Pigment cell & melanoma research 2019; (32(3)):373-380 doi:10.1111/pcmr.12748.

    PMID: 30387913

This page explains how Hermansky-Pudlak syndrome subtypes may shape health risks and monitoring for informational purposes only and does not constitute medical advice. A genetics or specialist care team can interpret your result and recommend surveillance for you or your child.